HC Wainwright Maintains Buy on Genmab with $50 Price Target
HC Wainwright & Co. has reiterated its Buy rating on Genmab's stock, setting a price target of $50.00. This target suggests a significant potential downside from the recent closing price.
HC Wainwright & Co. has reiterated its Buy rating on Genmab's stock, setting a price target of $50.00. This target suggests a significant potential downside from the recent closing price.